Menu
Search
|

Menu

Close
X

ChemoCentryx Inc CCXI.OQ (NASDAQ Stock Exchange Global Select Market)

12.32 USD
+0.03 (+0.20%)
As of Jul 20
chart
Previous Close 12.30
Open 12.30
Volume 49,478
3m Avg Volume 100,972
Today’s High 12.45
Today’s Low 12.15
52 Week High 15.08
52 Week Low 5.45
Shares Outstanding (mil) 49.15
Market Capitalization (mil) 604.55
Forward P/E 55.61
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
82
FY16
12
FY15
0
EPS (USD)
FY18
-0.193
FY17
0.290
FY16
-0.870
FY15
-1.078
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
55.61
33.34
Price to Sales (TTM)
vs sector
7.21
8.11
Price to Book (MRQ)
vs sector
23.69
4.23
Price to Cash Flow (TTM)
vs sector
40.66
22.22
Total Debt to Equity (MRQ)
vs sector
18.41
17.18
LT Debt to Equity (MRQ)
vs sector
18.41
13.08
Return on Investment (TTM)
vs sector
13.43
13.18
Return on Equity (TTM)
vs sector
40.19
15.09

EXECUTIVE LEADERSHIP

Thomas Schall
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $550,000.00
Bonus: --
Susan Kanaya
Executive Vice President, Chief Financial and Administrative Officer, Secretary, Since 2016
Salary: $400,000.00
Bonus: --
William Fairey
Chief Operating Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
Israel Charo
Senior Vice President - Research, Since
Salary: --
Bonus: --
Markus Cappel
Chief Business Officer, Treasurer, Since 2007
Salary: $354,543.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

850 Maude Ave
MOUNTAIN VIEW   CA   94043-4022

Phone: +1650.2102900

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

SPONSORED STORIES